Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications.

ABSTRACT:

Abstract

Peptide-drug conjugates (PDCs) have emerged as a promising strategy in cancer therapy, offering improved therapeutic efficacy and reduced toxicity. Compared to antibody-drug conjugates (ADCs) and small molecule-drug conjugates (SMDCs), PDCs possess distinct advantages, such as lower immunogenicity, improved tumor penetration, and simpler synthesis. This review discusses the latest advancements in PDC design, including novel peptide targeting mechanisms, linker selection, and formulation improvements for increased stability. Additionally, it explores the expanding clinical applications of PDCs and examines their limitations. The aim of this review is to provide a comprehensive overview of current PDC progress and outline future directions for their role in cancer treatment.

SUBMITTER: Tan R 

PROVIDER: S-EPMC12815524 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature